Entrada Therapeutics (TRDA) to Release Quarterly Earnings on Tuesday

Key Points

• Entrada Therapeutics is set to announce its Q2 2025 earnings results on August 12th, with analysts expecting a loss of ($0.86) per share and revenue of $8.17 million.
• In the last quarterly report on May 8th, the company reported an EPS of ($0.42), exceeding estimates, though revenue fell short of expectations.
• Insider sales occurred recently, with Director Kush Parmar selling 75,000 shares at an average price of $6.91, indicating potential shifts in confidence among stakeholders.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) is expected to announce its Q2 2025 earnings results before the market opens on Tuesday, August 12th. Analysts expect the company to announce earnings of ($0.86) per share and revenue of $8.17 million for the quarter.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.78) by $0.36. Entrada Therapeutics had a return on equity of 5.84% and a net margin of 14.39%. The business had revenue of $8.75 million for the quarter, compared to analyst estimates of $10.98 million. On average, analysts expect Entrada Therapeutics to post $1 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Entrada Therapeutics Trading Down 0.9%

Entrada Therapeutics stock traded down $0.06 during mid-day trading on Tuesday, hitting $5.87. The company had a trading volume of 43,075 shares, compared to its average volume of 138,531. Entrada Therapeutics has a 12-month low of $5.62 and a 12-month high of $21.79. The company has a market capitalization of $222.59 million, a price-to-earnings ratio of 7.23 and a beta of -0.12. The company's fifty day moving average is $7.08 and its 200-day moving average is $9.16.

Analysts Set New Price Targets

Several equities analysts have weighed in on TRDA shares. Wall Street Zen raised Entrada Therapeutics from a "sell" rating to a "hold" rating in a research report on Friday, June 27th. HC Wainwright reaffirmed a "buy" rating and set a $20.00 price target on shares of Entrada Therapeutics in a research report on Tuesday, May 20th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Entrada Therapeutics has a consensus rating of "Buy" and a consensus price target of $25.67.

Insider Transactions at Entrada Therapeutics

In related news, Director Kush Parmar sold 75,000 shares of the firm's stock in a transaction that occurred on Friday, June 27th. The stock was sold at an average price of $6.91, for a total value of $518,250.00. Following the sale, the director directly owned 1,113,092 shares in the company, valued at $7,691,465.72. This trade represents a 6.31% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Ventures V. L.P. 5Am sold 55,735 shares of Entrada Therapeutics stock in a transaction dated Friday, June 27th. The stock was sold at an average price of $6.91, for a total value of $385,128.85. Following the transaction, the insider directly owned 3,220,287 shares in the company, valued at approximately $22,252,183.17. The trade was a 1.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 254,000 shares of company stock valued at $1,782,000 in the last three months. 8.11% of the stock is currently owned by company insiders.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.